Live Breaking News & Updates on Polivy|Page 2

Stay updated with breaking news from Polivy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Roche's Polivy Continues To Demonstrate Benefits In Previously Untreated DLBCL Patients In POLARIX

SOUTH SAN FRANCISCO (dpa-AFX) - Roche Holding AG (RHHBY) on Monday said it presented updated data from the late-stage POLARIX study of Polivy in people with previously untreated diffuse large B-cell ....

United States , Mabthera Rituxan , American Society Of Hematology , Roche Holding , American Society , Annual Meeting , Biologics License Application ,

F. Hoffmann-La Roche Ltd: Roche presents new and updated data for Polivy in previously untreated diffuse large B-cell lymphoma at ASH 2022

Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large ....

United States , Levi Garraway , Mabthera Rituxan , Gazyva Gazyvaro , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Loren Kalm , Nathalie Altermatt , American Society Of Hematology , Drug Administration , Roche Group , Head Of Global Product Development , Roche Group Media Relations , American Society , Annual Meeting , Chief Medical Officer , Global Product , Biologics License Application , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Previously Untreated Diffuse Largeb Cell ,

F. Hoffmann-La Roche Ltd: FDA accepts supplemental Biologics License Application for Roche's Polivy combination for people with previously untreated diffuse large B-cell lymphoma

First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase III POLARIX study ....

United States , Gazyvaro Gazyva , Mabthera Rituxan , Sabine Borngr , Gerard Tobin , Bruno Eschli , Venclexta Venclyxto , Birgit Masjost , Sileia Urech , Loren Kalm , Karsten Kleine , Nathalie Altermatt , Lymphoma Study Association , Roche Group , Roche Group Media Relations , Lymphoma Academic Research Organisation , Lugano Response Criteria , Dow Jones Sustainability Indices , Chugai Pharmaceutical ,

Genentech: FDA Accepts SBLA For Polivy Combination For Aggressive Blood Cancer

SOUTH SAN FRANCISCO (dpa-AFX) - The U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application or sBLA for Polivy (polatuzumab vedotin-piiq) in combination ....

United States , Rituxan Mabthera , European Commission , Drug Administration , Roche Group , More Such Health News , Biologics License Application ,

EU Approves Roche's Polivy Combination For Previously Untreated Diffuse Large B-cell Lymphoma

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) said that the European Commission has granted approval of Polivy or polatuzumab vedotin in combination with MabThera or rituximab plus cyclophosphamide ....

European Union , European Commission ,